Isolation and characterization of 2′-F-RNA aptamers against whole HIV-1 subtype C envelope pseudovirus

Biochemical and Biophysical Research Communications

Volumn 456, Issue 1, 2015, Pages 428-433

  London, Grace M ^a   Mayosi, Bongani M ^b   Khati, Makobetsa ^a,b  

^a DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Aptamers; Entry inhibition; Enveloped pseudotyped virus; HIV 1; SELEX

Indexed keywords

2' F RNA APTAMER; APTAMER; ENVELOPE PROTEIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; LIGAND; NUCLEIC ACID;

AFRICA SOUTH OF THE SAHARA; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN BA L); HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C ENVELOPE PSEUDOVIRUS; IC50; IN VITRO STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; SURFACE PROPERTY; TARGET CELL; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; CHEMISTRY; COMBINATORIAL CHEMISTRY; CONFORMATION; DRUG EFFECTS; HEK293 CELL LINE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL AGENTS; APTAMERS, NUCLEOTIDE; HEK293 CELLS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; NUCLEIC ACID CONFORMATION; NUCLEIC ACIDS; SELEX APTAMER TECHNIQUE;

EID: 84919643311     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.11.101     Document Type: Article

References (28)

1. WHO, UNAIDS report on the global AIDS epidemic 2013.
2. S. Rusconi, and S. La Seta Catamancio HIV-1 protease inhibitors in development Expert Opin. Investig. Drugs 11 2002 387 395
3. C.E. Baldwin, R.W. Sanders, and B. Berkhout Inhibiting HIV-1 entry with fusion inhibitors Curr. Med. Chem. 10 2003 1633 1642
4. E. Vazquez Maraviroc - new HIV drug. Emerging options need to be used wisely Posit. Aware 18 2007 18 19
5. S.M. Crowe, J. Mills, J. Kirihara, J. Boothman, J.A. Marshall, and M.S. McGrath Full-length recombinant CD4 and recombinant gp120 inhibit fusion between HIV infected macrophages and uninfected CD4-expressing T-lymphoblastoid cells AIDS Res. Hum. Retroviruses 6 1990 1031 1037
6. B.J. Doranz, K. Grovit-Ferbas, M.P. Sharron, S.H. Mao, M.B. Goetz, E.S. Daar, R.W. Doms, and W.A. O'Brien A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor J. Exp. Med. 186 1997 1395 1400
7. M. Khati, M. Schuman, J. Ibrahim, Q. Sattentau, S. Gordon, and W. James Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′-F-RNA aptamers J. Virol. 77 2003 12692 12698
8. H.T. Mufhandu, E.S. Gray, M.C. Madiga, N. Tumba, K.B. Alexandre, T. Khoza, C.K. Wibmer, P.L. Moore, L. Morris, and M. Khati UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C J. Virol. 86 2012 4989 4999
9. H.T. Mufhandu, K.B. Alexandre, E.S. Gray, L. Morris, and M. Khati HIV-1 subtype C primary isolates exhibit high sensitivity to an anti-gp120 RNA aptamer Retrovirology 9 2012 215
10. W.R. Lopes de Campos, N. Chirwa, G. London, L.S. Rotherham, L. Morris, B.M. Mayosi, and M. Khati HIV-1 subtype C unproductively infects human cardiomyocytes in vitro and induces apoptosis mitigated by an anti-gp120 aptamer PLoS One 9 2014 e110930
11. W.R. Lopes de Campos, D. Coopusamy, L. Morris, B.M. Mayosi, and M. Khati Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals Antimicrob. Agents Chemother. 53 2009 3056 3064
12. J.P. Moore, and R.W. Doms The entry of entry inhibitors: a fusion of science and medicine Proc. Natl. Acad. Sci. U.S.A. 100 2003 10598 10602
13. H.X. Liao, L.L. Sutherland, S.M. Xia, M.E. Brock, R.M. Scearce, S. Vanleeuwen, S.M. Alam, M. McAdams, E.A. Weaver, Z. Camacho, B.J. Ma, Y. Li, J.M. Decker, G.J. Nabel, D.C. Montefiori, B.H. Hahn, B.T. Korber, F. Gao, and B.F. Haynes A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses Virology 353 2006 268 282
14. P. Pitisuttithum, P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J.W. Tappero, and K. Choopanya Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand J. Infect. Dis. 194 2006 1661 1671
15. J. Hammonds, X. Chen, T. Fouts, A. DeVico, D. Montefiori, and P. Spearman Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization J. Virol. 79 2005 14804 14814
16. E.J. Platt, K. Wehrly, S.E. Kuhmann, B. Chesebro, and D. Kabat Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1 J. Virol. 72 1998 2855 2864
17. W.S. Pear, G.P. Nolan, M.L. Scott, and D. Baltimore Production of high-titer helper-free retroviruses by transient transfection Proc. Natl. Acad. Sci. U.S.A. 90 1993 8392 8396
18. L.J. Reed, and H. Muench A simple method of estimating fifty per cent endpoint Am. J. Hyg. 27 1938 493 497
19. D.C. Montefiori Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays Curr. Protoc. Immunol. 2005 (Chapter 12, Unit 12.11)
20. R. Karlsson, A. Michaelsson, and L. Mattsson Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system J. Immunol. Methods 145 1991 229 240
21. L. Gold, and H. Chen Selection of high-affinity RNA ligands to reverse transcriptase: inhibition of cDNA synthesis and RNase H activity Biochemistry 33 1994 8746 8756
22. D.H. Bunka, and P.G. Stockley Aptamers come of age - at last Nat. Rev. Microbiol. 4 2006 588 596
23. W. James Nucleic acid and polypeptide aptamers: a powerful approach to ligand discovery Curr. Opin. Pharmacol. 1 2001 540 546
24. R. Wyatt, and J. Sodroski The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens Science 280 1998 1884 1888
25. V. Yoon, M. Fridkis-Hareli, S. Munisamy, J. Lee, D. Anastasiades, and L. Stevceva The GP120 molecule of HIV-1 and its interaction with T cells Curr. Med. Chem. 17 2010 741 749
26. S.C. Gopinath, K. Kawasaki, and P.K. Kumar Selection of RNA-aptamer against human influenza B virus Nucleic Acids Symp. Ser. (Oxf) 2005 85 86
27. L.M. Walker, S.K. Phogat, P.Y. Chan-Hui, D. Wagner, P. Phung, J.L. Goss, T. Wrin, M.D. Simek, S. Fling, J.L. Mitcham, J.K. Lehrman, F.H. Priddy, O.A. Olsen, S.M. Frey, P.W. Hammond, S. Kaminsky, T. Zamb, M. Moyle, W.C. Koff, P. Poignard, and D.R. Burton Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target Science 326 2009 285 289
28. P.L. Moore, E.S. Gray, D. Sheward, M. Madiga, N. Ranchobe, Z. Lai, W.J. Honnen, M. Nonyane, N. Tumba, T. Hermanus, S. Sibeko, K. Mlisana, S.S. Abdool Karim, C. Williamson, A. Pinter, and L. Morris Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop J. Virol. 85 2011 3128 3141